Skip to main
OSCR
OSCR logo

Oscar Health (OSCR) Stock Forecast & Price Target

Oscar Health (OSCR) Analyst Ratings

Based on 8 analyst ratings
Sell
Strong Buy 0%
Buy 0%
Hold 38%
Sell 50%
Strong Sell 13%

Bulls say

Oscar Health Inc. demonstrated strong financial performance in the second quarter of 2025, with revenue reaching $2.86 billion, marking a significant year-over-year increase of 29%, driven by robust member retention and additions during the special enrollment period. The company's Medical Loss Ratio (MLR) improved to 91.1%, showing a positive shift of 1,200 basis points year-over-year and a substantial 1,560 basis points increase sequentially, despite pressures from unanticipated marketwide morbidity. Further supporting a positive outlook, management anticipates an uptick in utilization in the fourth quarter of 2025, indicating confidence in the company's growth trajectory and operational effectiveness.

Bears say

Oscar Health reported a significant operating loss of $230.5 million for the second quarter of 2025, aligning with previous announcements but indicating ongoing financial distress. Additionally, the company's adjusted EBITDA of -$199.4 million fell short of consensus expectations, further highlighting its challenges in achieving profitability. Furthermore, management projects a decline in Individual membership towards the year's end, which could adversely impact future revenue growth and stability.

Oscar Health (OSCR) has been analyzed by 8 analysts, with a consensus rating of Sell. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 38% suggest Holding, 50% advise Selling, and 13% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oscar Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oscar Health (OSCR) Forecast

Analysts have given Oscar Health (OSCR) a Sell based on their latest research and market trends.

According to 8 analysts, Oscar Health (OSCR) has a Sell consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oscar Health (OSCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.